Pseudomonas eradication in cystic fibrosis: Who will join the ELITE?

Thorax

Volumn 65, Issue 4, 2010, Pages 281-282

  Smyth, Alan R ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COLISTIN; TOBRAMYCIN;

EDITORIAL; ERADICATION THERAPY; HUMAN; LUNG FIBROSIS; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; RECURRENT INFECTION; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77950898714     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.130708     Document Type: Editorial

References (17)

1. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704. (Pubitemid 32417671)
2. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100. (Pubitemid 34809519)
3. Drenkard E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 2003;5:1213-1219 (Pubitemid 37410254)
4. Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009;44:547-558
5. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-588 (Pubitemid 40171240)
6. Valerius N, Koch CHN. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-726
7. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005;4 Suppl 2:49-54. (Pubitemid 41131329)
8. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849 (Pubitemid 36801771)
9. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92. (Pubitemid 28110583)
10. Proesmans M, Boulanger L, Vermeulen F, et al. Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin/ciprofloxacin. J Cyst Fibros 2008;7:S64.
11. Ratjen F, Munck A, Kho P, et al, for the ELITE study group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-291
12. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36-39 (Pubitemid 26229889)
13. Doring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767
14. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009;(4):CD004197.
15. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009;30:256-268
16. Cheney J, Vidmar S, Grimwood K, et al. Interim outcomes of a Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study. J Cyst Fibros 2009;8:S39.
17. UK Cysic Fibrosis Trust. UK CF Registry. Annual Data Report 2008. Bromley: Cystic Fibrosis Trust, 2009.